Early day motion tabled by primary sponsor Mark Durkan (Social Democratic & Labour Party), on Wednesday, 29 October 2014, in the House of Commons. It is signed by 21 members in total.
GLOBAL HEALTH - RESEARCH AND DEVELOPMENT PARTNERSHIPS
That this House pays tribute to the highly valuable and effective research and development (R&D) work into innovative global health goods carried out by public-private partnerships such as the European and Developing Countries Clinical Trials Partnership, the International AIDS Vaccine Alliance and the TB Alliance; highlights the important work these partnerships have done to accelerate the development of new or improved treatments, vaccines, microbicides, formulations and diagnostics against HIV/AIDS, tuberculosis and malaria with a focus on efficacy and implementation in affected regions such as sub-Saharan Africa; recognises that this work meets an urgent demand not currently met by market-based models of medical R&D and allows the integration and co-ordination of international research and the development of long-term medical research capacity in developing countries; and calls on the Government to maintain and employ its position as a leading funder of such partnerships to encourage increased contributions from other donor countries and private sector partners, particularly European Union member states.
Secondary information
- Type
- Early day motion
- Reference
- 439
- Session
- 2014-15
- Other sponsors
- Kelvin Hopkins
- Jeremy Corbyn
- Mike Hancock
- Virendra Sharma
- Jim Shannon
- Subjects
- Health Expenditure Innovation Science
- Link
- View this Early day motion on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-10-06 20:24:58 +0100
- URI
- http://data.parliament.uk/edms/47278
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/edms/47278
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/edms/47278